Related Experiment Videos
[Bone marrow transplantation in chronic myeloid leukemia]
1Kliniki Hematologii AM, Poznaniu.
Acta Haematologica Polonica
|January 1, 1992
Summary
Bone marrow transplantation (BMT) offers a cure for chronic myelogenous leukemia (CML). Optimal outcomes for CML patients involve HLA-matched sibling transplants early in the disease, with unrelated donors and autologous transplants serving as alternatives.
Area of Science:
- Hematology
- Oncology
- Stem Cell Transplantation
Background:
- Chronic myelogenous leukemia (CML) is a hematologic malignancy.
- Bone marrow transplantation (BMT) is the sole curative treatment for CML.
- Treatment success is influenced by donor match, disease phase, patient age, and timing.
Purpose of the Study:
- To outline the current role and indications for BMT in CML management.
- To discuss the benefits of HLA-matched sibling BMT.
- To explore alternative BMT strategies for CML patients.
Main Methods:
- Review of existing literature on BMT for CML.
- Analysis of factors influencing BMT outcomes.
- Evaluation of different BMT approaches (allogeneic, autologous).
Main Results:
- HLA-matched sibling BMT within one year of diagnosis offers the best outcomes for CML.
- BMT from HLA-matched unrelated donors expands treatment options for patients lacking sibling donors.
- Autologous BMT is considered for interferon-refractory CML or high-risk patients.
Conclusions:
- BMT remains a critical curative therapy for CML.
- Patient selection and transplant type are key determinants of successful CML treatment.
- Advancements in BMT continue to improve therapeutic options for CML patients.